智通财经网·2026-01-15 00:56Core Insights - WuXi AppTec (603259.SH, 02359) announced the latest progress of its GLP-1 drug pipeline at the 44th JPMorgan Healthcare Conference, revealing support for 24 GLP-1 drugs [1] - The company is developing 24 GLP-1 drugs, including both small molecules and peptides, with 15 already in Phase II and III clinical trials, positioning the company to capture approximately 25% of the global GLP-1 market [1] - The ongoing shortage of GLP-1 drugs highlights deficiencies in the core pharmaceutical supply chain, with demand experiencing unprecedented exponential growth [1] Industry Developments - Some pharmaceutical companies have successfully navigated shortages by efficiently outsourcing to selected external partners while mobilizing internal resources, demonstrating flexible and expanding production methods [1] - As a key player in the global core pharmaceutical supply chain, WuXi AppTec has proactively built its production capacity, recently completing the construction of a 100,000-liter solid-phase synthesis reactor to enhance large-scale production capabilities [1] - The increasing accessibility of GLP-1 drugs is expected to reshape the treatment landscape for obesity and related metabolic diseases, indicating the beginning of a "therapeutic revolution" [1]